These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 10372262)

  • 1. Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin.
    Blonde L; Sandberg MI; Guthrie RD
    Diabetes Care; 1999 Jun; 22(6):1004-6. PubMed ID: 10372262
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
    Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
    Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
    Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD
    Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
    Hershon KS; Hershon PM
    Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The polycystic ovary syndrome: treatment with insulin sensitizing agents.
    Iuorno MJ; Nestler JE
    Diabetes Obes Metab; 1999 May; 1(3):127-36. PubMed ID: 11220291
    [No Abstract]   [Full Text] [Related]  

  • 6. [Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
    Ohmura E; Hosaka D; Imai Y; Kawazu S
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():470-5. PubMed ID: 12387036
    [No Abstract]   [Full Text] [Related]  

  • 7. Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
    Krentz AJ; Bailey CJ; Melander A
    BMJ; 2000 Jul; 321(7256):252-3. PubMed ID: 10915108
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.
    Schwartz S; Raskin P; Fonseca V; Graveline JF
    N Engl J Med; 1998 Mar; 338(13):861-6. PubMed ID: 9516220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using dose-response characteristics of therapeutics agents for treatment decisions in type 2 diabetes.
    Garber AJ
    Diabetes Obes Metab; 2000 Jun; 2(3):139-47. PubMed ID: 11220549
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of troglitazone on insulin sensitivity.
    Henry RR
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S148-50. PubMed ID: 8894499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
    Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
    Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rise and fall of troglitazone.
    Bailey CJ
    Diabet Med; 2000 Jun; 17(6):414-5. PubMed ID: 10975209
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes.
    Strowig SM; Avilés-Santa ML; Raskin P
    Diabetes Care; 2002 Oct; 25(10):1691-8. PubMed ID: 12351463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy in type 2 diabetes: the role of repaglinide.
    Moses R
    J Assoc Physicians India; 2001 Jan; 49 Spec No():62-8. PubMed ID: 11235608
    [No Abstract]   [Full Text] [Related]  

  • 15. Insulin sensitizers for polycystic ovary syndrome.
    Baillargeon JP; Iuorno MJ; Nestler JE
    Clin Obstet Gynecol; 2003 Jun; 46(2):325-40. PubMed ID: 12808383
    [No Abstract]   [Full Text] [Related]  

  • 16. Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success.
    Nagasaka S; Abe T; Kawakami A; Kusaka I; Nakamura T; Ishikawa S; Saito T; Ishibashi S
    Diabet Med; 2002 Apr; 19(4):347-8. PubMed ID: 11943013
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of troglitazone in patients with type 2 diabetes mellitus not adequately controlled by sulfonylureas.
    Bunnag P; Puavilai G; Chanprasertyotin S; Chandraprasert S; Suwanwalaikorn S; Suthijumroon A; Benjasuratwong Y; Boonyavarakul A; Nitiyanant W; Sriussadaporn S; Deerochanawong C;
    Diabetes Res Clin Pract; 2001 Feb; 51(2):151-3. PubMed ID: 11253769
    [No Abstract]   [Full Text] [Related]  

  • 18. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones.
    King AB
    Diabetes Care; 2000 Apr; 23(4):557. PubMed ID: 10857952
    [No Abstract]   [Full Text] [Related]  

  • 19. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.
    Fonseca VA; Valiquett TR; Huang SM; Ghazzi MN; Whitcomb RW
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3169-76. PubMed ID: 9745421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.
    Raskin P; Jovanovic L; Berger S; Schwartz S; Woo V; Ratner R
    Diabetes Care; 2000 Jul; 23(7):979-83. PubMed ID: 10895850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.